News | June 24, 2024
AstraZeneca Pharma India updates on exploring contract manufacturer
The company will now explore a buyer for its manufacturing site and exit in due course
The company will now explore a buyer for its manufacturing site and exit in due course
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Subscribe To Our Newsletter & Stay Updated
